Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUS-GBD vs Antibiotics First for Acute Cholecystitis in High-Risk Patients
NCT05893511Phase 3Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Apr 2023
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute cholecystitis (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: 1-year recurrent acute cholecystitis rate. Started Apr 2023; status: recruiting.
02
Conditions
acute cholecystitis
Beyond the preview
Go deeper on NCT05893511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05893511.